Third Harmonic Bio Inc.

NASDAQ THRD

Data sourced from

and

Download Data

Third Harmonic Bio Inc. Dividend Coverage Ratio for the year ending December 31, 2023

Third Harmonic Bio Inc. Dividend Coverage Ratio is NA for the year ending December 31, 2023. The dividend coverage ratio measures a company's ability to cover its dividend payments with its net income. It is calculated by dividing net income by dividends paid. This ratio indicates the proportion of net income that is allocated to paying dividends. A ratio greater than 1 suggests sufficient income to cover dividend payments, while a ratio less than 1 indicates a potential shortfall.

NASDAQ: THRD

Third Harmonic Bio Inc.

CEO	Ms. Natalie C. Holles
IPO Date	Sept. 14, 2022
Location	United States
Headquarters	300 Technology Square, Cambridge, MA, United States, 02139
Employees	31
Sector	Healthcare
Industry	Biotechnology

Description

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.

Key trends